open access

Vol 23, No 1 (2020)
Clinical vignette
Published online: 2020-01-31
Submitted: 2019-07-25
Accepted: 2019-12-19
Get Citation

99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair

Sara Shakeri, Parinaz Jahanpanah, Ghasemali Divband, Toktam Massoudi, Kamran Aryana
DOI: 10.5603/NMR.2020.0011
·
Pubmed: 32779178
·
Nucl. Med. Rev 2020;23(1):49-50.

open access

Vol 23, No 1 (2020)
Clinical vignette
Published online: 2020-01-31
Submitted: 2019-07-25
Accepted: 2019-12-19

Abstract

Brain metastases of PTC are rare and occur in 0.1-5% of the patients, especially in the poorly differentiated types that usually fail to concentrate iodine. We present a rare case of PTC with probable brain metastasis in a 58-year-old woman with a history of poorly differentiated PTC that showed elevated Tg levels and no metastasis was detected in the whole-body iodine scan, despite the positive 99m Tc-octreotide scintigraphy. This imaging modality could be helpful as a diagnostic guide for radionuclide therapy with labeled somatostatin analogs in cases of thyroid carcinoma with elevated Tg levels and negative whole-body iodine scan.

Abstract

Brain metastases of PTC are rare and occur in 0.1-5% of the patients, especially in the poorly differentiated types that usually fail to concentrate iodine. We present a rare case of PTC with probable brain metastasis in a 58-year-old woman with a history of poorly differentiated PTC that showed elevated Tg levels and no metastasis was detected in the whole-body iodine scan, despite the positive 99m Tc-octreotide scintigraphy. This imaging modality could be helpful as a diagnostic guide for radionuclide therapy with labeled somatostatin analogs in cases of thyroid carcinoma with elevated Tg levels and negative whole-body iodine scan.

Get Citation

Keywords

Papillary thyroid carcinoma; 99m Tc-octreotide scintigraphy; whole-body iodine

About this article
Title

99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair

Journal

Nuclear Medicine Review

Issue

Vol 23, No 1 (2020)

Pages

49-50

Published online

2020-01-31

DOI

10.5603/NMR.2020.0011

Pubmed

32779178

Bibliographic record

Nucl. Med. Rev 2020;23(1):49-50.

Keywords

Papillary thyroid carcinoma
99m Tc-octreotide scintigraphy
whole-body iodine

Authors

Sara Shakeri
Parinaz Jahanpanah
Ghasemali Divband
Toktam Massoudi
Kamran Aryana

References (8)
  1. Tsuda K, Tsurushima H, Takano S, et al. Brain metastasis from papillary thyroid carcinomas. Mol Clin Oncol. 2013; 1(5): 817–819.
  2. Lowe VJ, Mullan BP, Hay ID, et al. 18F-FDG PET of patients with Hürthle cell carcinoma. J Nucl Med. 2003; 44(9): 1402–1406.
  3. Zhang H, Zeng L, Liang C, et al. Successful treatment of Hurthle cell thyroid carcinoma with lung and liver metastasis using docetaxel and cisplatin. Jpn J Clin Oncol. 2012; 42(11): 1086–1090.
  4. Khan S, Sharibi A, Neff R, et al. Metastatic Hürthle cell carcinoma: a unique case report and review of the literature. Endocr Pract. 2005; 11(4): 285–289.
  5. Pryma DA, Schöder H, Gönen M, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006; 47(8): 1260–1266.
  6. Shinto AS, Kamaleshwaran KK, Mallia M, et al. Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. World J Nucl Med. 2015; 14(2): 101–108.
  7. Haslinghuis LM, Krenning EP, De Herder WW, et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001; 24(6): 415–422.
  8. Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996; 81(7): 2541–2544.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl